YBX1 and melanoma: Multiple pathways are involved such as YB‐1 dephosphorylation, suppression of mesenchymal markers, reduction in transcript levels and matrix‐metalloproteinases, inhibition of RSK activity through binding to the kinase, inhibition of YB‐1/RSK signaling independent of its effect on ERK, and reduction in MDR1 levels in melanoma cells (Sechi et al., 2018).